TRx0237 (Alzheimer’s Disease)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.2 Symptoms 28
4 Disease Management 30
4.1 Diagnosis 30
4.1.1 Probable Alzheimer’s Disease Dementia 31
4.1.2 Possible AD Dementia 32
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 32
4.1.4 Possible Alzheimer’s Dementia with Evidence of the Alzheimer’s Disease Pathophysiological Process 33
4.1.5 Preclinical AD 33
4.1.6 Mild Cognitive Impairment 34
4.2 Treatment Overview 36
5 Competitive Assessment 39
5.1 Overview 39
5.2 Strategic Competitor Assessment 39
6 Opportunity and Unmet Need 42
6.1 Unmet Needs Overview 42
6.1.1 Public Awareness 44
6.1.2 Specialized Institutions at Local Levels 45
6.1.3 Screening and Diagnosis 45
6.1.4 Early Intervention 46
6.1.5 Improved Clinical Trial Design 47
6.1.6 Effective Therapy 48
6.1.7 Behavioral Treatments 49
6.2 Gap Analysis 49
6.2.1 Disease Prevention 50
6.2.2 Diagnosis from Biomarkers 51
6.2.3 Behavioral Therapies 52
7 Pipeline Assessment 53
7.1 Overview 53
7.2 Early-Stage Pipeline Assessment 54
7.3 AD Pipeline by Mechanism of Action 56
7.4 Enzymatic Processing 56
7.5 Immunization 57
7.6 Anti-Aggregation 58
7.7 “Me-Too” 58
7.8 Novel Therapeutic Approaches 59
7.9 Technology Trends Analytic Framework 60
7.10 Promising Drugs in Clinical Development 61
8 TRx0237 64
8.1 Overview 64
8.2 Efficacy 65
8.3 Safety 65
8.4 Dosing and Formulation 66
8.5 Potential Clinical Positioning 66
8.6 Pricing and Reimbursement 66
8.7 SWOT Analysis 67
8.8 Forecast 67
9 Appendix 68
9.1 Bibliography 68
9.2 Abbreviations 73
9.3 Methodology 76
9.4 Forecasting Methodology 76
9.4.1 Diagnosed AD patients 77
9.4.2 Percent Drug-treated Patients 77
9.4.3 General Pricing Assumptions 77
9.4.4 Generic Erosion 78
9.4.5 Pricing of Pipeline Agents 78
9.4.6 Alternate Scenarios 79
9.5 Physicians and Specialists Included in this Study 79
9.6 About the Authors 80
9.6.1 Author 80
9.6.2 Global Head of Healthcare 81
9.7 About GlobalData 82
9.8 Disclaimer 82